Individuals Stopping Slimming Injections Gain Back Pounds Far More Rapidly Than People Using Diet and Exercise

A recent study suggests that people who stop using new slimming jabs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.

Published data in a leading medical journal demonstrates that while overweight individuals can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month after stopping.

"Users purchasing such medications need to be informed of the risk of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.

Such speed of recovery suggests a reversion to starting mass in about 18 months.

Analyzing Therapies

The study, which examined dozens of studies involving thousands of participants, compared the results of GLP-1 agonists with older methods.

The team point out that individuals who shed pounds through lifestyle changes alone generally experience a less rapid creep back—approximately 100 grams monthly—post-intervention.

Explaining the Rapid Regain

Nutrition scientists believe the mode of action of the injections explains the accelerated weight return.

These medications copy a body's own chemical called GLP-1, which moderates hunger.

"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating far more likely."

A Lifelong Disease?

The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.

A number of clinicians contend that, considering the significant potential of weight regain, the treatment is often ongoing.

This perspective is echoed by drug manufacturers, who state that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like high blood pressure.

User Experiences

Individuals who have discontinued the jabs report a sudden resurgence of hunger.

"It felt as if a switch flipping and you become extremely hungry," described an individual.

The struggle is compounded if users have not established sustainable dietary or behavioural modifications during treatment.

Significant Use

Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is greater among women than males.
• The middle-aged age group shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on integrated behavioural support.